98%
921
2 minutes
20
Epidemiological evidence regarding the association between vitamins and diabetic complications remains inconsistent. This study aims to explore the potential causal relationships between diabetic complications and circulating vitamins in diabetics. We selected vitamin A (VitA) genetic variants ( = 5,006), vitamin B (VitB) genetic variants ( = 64,974), vitamin C (VitC) genetic variants ( = 52,018) and vitamin D (VitD) genetic variants ( = 441,291) as exposures of interest from large-scale Genome-Wide Association Studies (GWAS) databases. Then we performed two-sample Mendelian randomization (MR) analyses to evaluate the causal association of plasma vitamin levels with diabetic complications, which included maculopathy, ketoacidosis, hypoglycemia, neuropathy, nephropathy and retinopathy. Multiple methods were performed and used including the inverse-variance weighted (IVW), the weighted median, MR-Egger and MR-PRESSO regression. Heterogeneity and sensitivity analyses were conducted. The results of the IVW method revealed that the level of VitB were associated with diabetic hypoglycemia with (OR: 8.54; 95% CI: 1.77 to 41.2; : 0.01). No association was detected between other vitamins (VitA, VitC or VitD) and diabetic complications (maculopathy, ketoacidosis, hypoglycemia, neuropathy, nephropathy or retinopathy). After MR-PRESSO analysis, there was no causal relationship detected between VitD and diabetic hypoglycemia (OR: 0.867, CI: 0.64 to 1.18, : 0.37), diabetic ketosis (OR: 0.763515, CI: 0.58 to 1.00, : 0.055), diabetic maculopathy (OR: 0.72, CI: 0.48 to 1.07, : 0.105). This analysis provided genetic evidence that the level of VitB may be the risk factor for diabetic hypoglycemia. VitA, VitC, or VitD were not associated with various diabetic complications. Monitoring for excess VitB and suitable supplements might be important, and other vitamins may have limited effects in complications prevention, and further investigations were needed to unveil the mechanisms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230352 | PMC |
http://dx.doi.org/10.1002/fsn3.70536 | DOI Listing |
PLoS One
September 2025
The Permanente Medical Group, Pleasanton, California, United States of America.
Background: Research on Post-acute sequelae of COVID (PASC) has focused on the prevalence of symptoms, leaving gaps in our understanding of predictors of health care seeking.
Objective: To identify clinical and sociodemographic characteristics associated with PASC care seeking.
Methods: Retrospective cohort study of adult patients with COVID-19 diagnosis between January 1, 2021 and June 30, 2022 in a community-based comprehensive health care delivery system at 21 hospitals and medical clinics in Northern California.
Introduction: Genetic analysis is essential for diagnosing, treating, and predicting complications in neonatal diabetes mellitus (NDM) but is unavailable in some regions. Sulfonylureas are effective for NDM caused by KCNJ11 or ABCC8 mutations, which are among the most common genetic causes, therefore they are often given before genetic testing. Unfortunately, in certain ethnicities, this mutation rarely occurs.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.
Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.
Diabetes Ther
September 2025
Eli Lilly and Company, Lilly Corporate Center, 893 Delaware Street, Indianapolis, IN, 46225, USA.
Introduction: This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA).
Methods: The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis.
Diabetologia
September 2025
Centre Universitaire de Diabétologie et de ses Complications, AP-HP, Hôpital Lariboisière, Paris, France.
Aims/hypothesis: Severe hypoglycaemia events (SHE) remain frequent in people with type 1 diabetes despite advanced diabetes technologies. We examined whether time below range (TBR) 3.9 mmol/l (70 mg/dl; TBR70) or 3.
View Article and Find Full Text PDF